Fresenius Medical Care (NYSE: FMS) reported Q3 EPS of EUR0.57, EUR0.28 better than the analyst estimate of EUR0.29. Revenue for the quarter came in at EUR4.94 billion versus the consensus estimate of EUR5.32 billion.

OUTLOOK

The Company continues to expect for 2023 revenue to grow at a low to mid-single digit percentage rate (2022 basis: EUR 19,398 million).

Based on the earnings development for the first nine months of the year and solid business expectations for the remainder of the year, Fresenius Medical Care raises its earnings outlook for 2023. The Company now expects operating income to grow at a low-single digit percentage rate (2022 basis: EUR 1,540 million; previous target: remain flat or decline by up to a low-single digit percentage rate).

The Company's target to achieve an operating income margin of 10 to 14% by 2025 remains unchanged.

For earnings history and earnings-related data on Fresenius Medical Care (FMS) click here.